Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.

Abstract

Background: Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is challenging. Salvage whole-brain radiation therapy (WBRT) is an option but has a short duration of disease control, so additional treatment modalities are warranted. Case: A 75-year-old female with r/r PCNSL who had multipleprogressions after multiple lines of treatment underwent salvage WBRT. The patient received ibrutinib, a Bruton's tyrosine kinase inhibitor, as maintenance therapy for 18months following WBRT with the intention of increasing survival duration after salvage WBRT. She survived 81months from diagnosis, including 57months after completion of WBRT. Conclusion: Thiscase presentation describes the experience ofusing ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.